Welcome to our dedicated page for RetinalGenix Technologies SEC filings (Ticker: RTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RetinalGenix Technologies filings document public-company reporting status, financial-statement timing, and governance changes for a developmental-stage company focused on retinal imaging, genetic testing, and pharmacogenetic mapping. The record includes a Form 12b-25 notification related to the timing of its annual report and an 8-K reporting an executive officer resignation, with disclosures centered on reporting obligations, financial statement finalization, and management structure.
RetinalGenix Technologies Inc. reported no revenue for the three and six months ended June 30, 2026 and continues to operate as a pre-commercial ophthalmic R&D company. Net loss was $307,397 for the quarter and $897,886 for the first half, narrower than the prior-year periods, driven mainly by lower general and administrative and stock-based compensation expenses, partially offset by higher research and development spending on the RetinalCam project.
At June 30, 2026, cash was $27,232 against total liabilities of $2,672,914 and an accumulated deficit of $18,756,503, leaving a stockholders’ deficit of $2,640,699. The company discloses substantial doubt about its ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance product development, genetic testing, and its AI database. Operations remain heavily supported by related party Sanovas, to which $996,007 was owed at June 30, 2026; this balance was subsequently exchanged for 442,670 common shares.
The company sold 88,889 shares at $2.25 per share during the period, maintains significant potential dilution through 780,000 stock options, 1,950,000 warrants, and a 28,014,540-share pre-funded warrant, and reports a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies Inc. reported that Liebman Hymowitz, LLP resigned as its independent registered public accounting firm, effective July 13, 2026. Liebman Hymowitz’s audit reports on the consolidated financial statements for the years ended December 31, 2025 and December 31, 2024 were unqualified but included an explanatory paragraph describing substantial doubt about the company’s ability to continue as a going concern. The company states there were no disagreements with Liebman Hymowitz on accounting principles, financial statement disclosure, or auditing scope or procedures, and no reportable events other than previously disclosed issues involving internal control over financial reporting and disclosure controls and procedures.
On July 15, 2026, RetinalGenix engaged Vilki & Co., Charted Accountants as its new independent registered public accounting firm for the year ending December 31, 2026. The company indicates it did not consult Vilki & Co. in advance on accounting principles, potential audit opinions, or any matters involving disagreements or reportable events. RetinalGenix has requested a letter from Liebman Hymowitz addressed to the SEC confirming its agreement with these disclosures, to be filed as Exhibit 16.1.
Alpine Securities Corporation (RTGN) submitted a Form 144 notice proposing the sale of 4,214,000 common shares via exercise of warrants. The filing shows a recent reported sale by Bayern Capital LLC of 500 common shares on 05/04/2026 for $1,685.90. The issuer is listed at 39 Exchange Place, Salt Lake City, UT, and the securities trade on OTCQB.
RetinalGenix Technologies Inc. reported another quarterly loss and severe liquidity pressure for the quarter ended March 31, 2026. The company generated no revenue and recorded a net loss of $590,489, similar to the prior year period, driven by $262,149 of general and administrative costs, $117,064 of research and development, and $210,016 of stock-based compensation.
Cash fell to just $180 at March 31, 2026 against total liabilities of $2,563,889 and an accumulated deficit of $18,449,106, leaving a significant stockholders’ deficit. Management discloses “substantial doubt” about the company’s ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance its retinal imaging devices, DNA/GPS genetic testing platform, and related AI database toward commercialization. Operations remain heavily supported by related-party Sanovas, which is owed about $830,632. The filing also notes a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies Inc. files its annual report describing a development-stage ophthalmic business with no product revenue and recurring net losses. The company focuses on four pillars: genetic testing, retinal imaging, a patient information database, and repurposed pharmaceutical therapies for dry age-related macular degeneration and Alzheimer’s dementia.
Management plans initial genetic test sales and beta retinal imaging in 2026 and potential commercialization in 2027, but discloses substantial doubt about its ability to continue as a going concern. RetinalGenix estimates it needs about $7 million in additional funding and has recently raised smaller amounts through private stock placements.
RetinalGenix Technologies Inc. reported that its Chief Financial Officer, Michael Cory Zwerling, resigned from his position, effective immediately on March 22, 2026. The company did not provide additional details about the circumstances of his departure or plans for a successor in this report.
RetinalGenix Technologies (RTGN) filed its Q3 2025 10‑Q, reporting no revenue and a smaller quarterly net loss of $568,791 versus $644,291 a year ago. Operating expenses fell to $567,833 on lower R&D and stock‑based compensation, while interest expense was negligible.
Liquidity is strained: cash was $92 at September 30, 2025 against total liabilities of $2,179,731 and a stockholders’ deficit of $(2,172,730). The company discloses “substantial doubt” about its ability to continue as a going concern and is in discussions to raise capital and explore a potential up‑listing. Related‑party payables include $539,052 due to Sanovas as of quarter‑end.
For the nine months, net loss improved to $1,805,468 from $3,453,800 on sharply lower stock‑based compensation. RTGN sold 82,666 shares for $186,000 year‑to‑date and subsequently sold 12,000 shares for $27,000. A material weakness in internal control over financial reporting (lack of segregation of duties) remains. Common shares outstanding were 18,604,961 at November 14, 2025.